Tigecycline Therapy in an Infant for Ventriculoperitoneal Shunt Meningitis
dc.contributor.author | Emiroğlu, Melike | |
dc.contributor.author | Alkan, Gülsüm | |
dc.contributor.author | Dağı, Hatice Türk | |
dc.date.accessioned | 2020-03-26T19:43:14Z | |
dc.date.available | 2020-03-26T19:43:14Z | |
dc.date.issued | 2017 | |
dc.department | Selçuk Üniversitesi | en_US |
dc.description.abstract | Shunt infections are seen in 3% to 20% of patients who have cerebrospinal fluid (CSF) shunts. Although the staphylococcal species are the most common cause of shunt-related infections, Gram-negative bacteria are increasingly reported with higher mortality rates. Tigecycline, a glycylcycline, is not approved for children. But in the era of nosocomial infections due to multidrug-resistant pathogens, it can be the life-saving option. We report an infant with ventriculoperitoneal shunt-related meningitis treated with a tigecycline combination regimen. A 5-month-old boy who had a ventriculoperitoneal shunt was admitted with meningitis. Extended spectrum beta-lactamase-producing Klebsiella pneumoniae grew in the CSF. At the end of the fourth week of intravenous meropenem plus gentamicin therapy, carbapenem-resistant K pneumoniae grew in the CSF (mean inhibitory concentration value for meropenem >4 mu g/mL, by E-test). The infected shunt was removed, and an external ventricular drainage catheter was inserted. With permission, intravenous tigecycline (1.2 mg/kg per dose twice a day) and intrathecal amikacin were added to the meropenem. Intrathecal amikacin could be given for only 7 days. On the sixth day of tigecycline treatment, the CSF was sterilized. Antibiotic therapy was given and consisted of a total of 60 days of meropenem and 20 days of tigecycline therapy. Because no available efficacy and safety data from randomized-controlled studies exist, tigecycline must be used only as salvage therapy, in combination with other drugs, for critically ill children who have no alternative treatment options. | en_US |
dc.identifier.doi | 10.1542/peds.2016-0963 | en_US |
dc.identifier.issn | 0031-4005 | en_US |
dc.identifier.issn | 1098-4275 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | 27974589 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.uri | https://dx.doi.org/10.1542/peds.2016-0963 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12395/35632 | |
dc.identifier.volume | 139 | en_US |
dc.identifier.wos | WOS:000392122000012 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | AMER ACAD PEDIATRICS | en_US |
dc.relation.ispartof | PEDIATRICS | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.selcuk | 20240510_oaig | en_US |
dc.title | Tigecycline Therapy in an Infant for Ventriculoperitoneal Shunt Meningitis | en_US |
dc.type | Article | en_US |